Arsenic Trioxide Pretreatment for Normal Cell Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer treatments involving chemotherapy and radiation therapy often cause significant side effects in normal cells, limiting the maximum allowable dose and affecting the quality of life for patients due to systemic toxicity and adverse reactions.
Innovation Solution
Administering arsenic or arsenic compounds in therapeutically effective amounts before or during chemotherapy or radiation therapy to inhibit damage to non-cancerous cells, thereby reducing side effects such as gastrointestinal issues, low blood cell counts, and hair loss.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy or radiation therapy is administered to treat cancer cells, then cancer cells are killed, but normal cells are damaged causing systemic toxicity and adverse side effects
Solution Approach 1:
Arsenic trioxide is administered to patients at least one day prior to chemotherapy or radiation therapy to pretreat and protect normal cells from damage. This preliminary action allows arsenic trioxide to accumulate in normal cells and activate protective mechanisms before the cytotoxic treatment is applied, thereby reducing adverse side effects while maintaining cancer treatment efficacy.
2Productivity
If higher doses of chemotherapeutic agents are administered to improve cancer treatment efficacy, then cancer cell killing is enhanced, but toxicity to normal cells increases limiting the maximum allowable dose
Solution Approach 1:
Arsenic trioxide serves as a protective intermediary substance that is administered before chemotherapy or radiation therapy. It selectively accumulates in normal cells and activates protective pathways, creating a protective barrier that allows higher doses of cytotoxic agents to be administered without proportionally increasing damage to normal cells, thereby enabling enhanced cancer cell killing with acceptable toxicity levels.
Data Source
AI summary
A method of inhibiting damage to non-cancerous cells in a human subject during chemotherapeutic treatment or radiation treatment of cancer cells in the human subject includes administering to the human subject arsenic and/or one or more compounds of arsenic in a therapeutically effective amount prior to treatment with radiation or one or more chemotherapeutic agents.